PacBio high-fidelity near full-length genome sequencing for HIV-1 quasispecies: methodological framework and validation

PacBio高保真近全长基因组测序技术在HIV-1准种中的应用:方法框架及验证

阅读:2
作者:Bo Zhu,Xiaorui Wang,Hanping Li,Yongjian Liu,Lei Jia,Xiaolin Wang,Jingyun Li,Bohan Zhang,Jingwan Han,Wei Ma,Lin Li

Abstract

This study aimed to develop an optimized sequencing workflow for HIV-1 near full-length genome (NFLG) quasispecies, integrating the PacBio Revio platform with a streamlined bioinformatics pipeline to enable precise characterization of the genetic heterogeneity and dynamic evolution of HIV-1 quasispecies. To this end, the HIV-1 NFLG was divided into three segments for high-fidelity amplification and PacBio sequencing. This method achieved stable amplification (positivity rate >80%) in samples with a viral load >1,000 copies/mL and demonstrated applicability to China's five major epidemic strains and unique recombinant forms (URFs). The adoption of sample-specific asymmetric barcode sequences improved cost-effectiveness, enabling efficient sequencing of 300 to 1,000 samples per sequencing cell. The entire amplification-sequencing workflow exhibited minimal systematic errors (recombination rate <3.5%, average base variation rate <0.1%). Following bioinformatic processing including filtering, clustering, and screening, the sequencing data yielded multiple accurate viral quasispecies sequences with their approximate abundance profiles. Validation studies demonstrated excellent concordance with results from conventional single-genome amplification (SGA) and Sanger sequencing, while showing superior performance in quasispecies-level dual infection detection and recombinant pattern identification. In conclusion, this study developed a PacBio HiFi-based sequencing workflow for HIV-1 NFLG quasispecies, which exhibits robust high sensitivity, accuracy, and reproducibility. This approach provides a powerful tool for deepening understanding of HIV-1 evolution, dissecting genetic diversity, tracing transmission chains, and facilitating precision antiretroviral therapy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。